Presented by GSK The editorial staff did not participate in the production of this article.
130 million doses per year
With 600 million euros invested in its construction in 2011, and 17 million just last year, this industrial site covering an area of 14 hectares is equipped with high added value technologies. This is to ensure 24 hours a day, 7 days a week, the manufacture of a wide range of vaccines, including a revolutionary antimalarial. GSK Saint-Amand-les-Eaux employs nearly 1,000 people and recruits and trains qualified technicians. What if you got involved alongside them to respond to major public health issues?
The recent health crisis has highlighted the need to keep not only research centers on national and European territory, but also tools for producing drugs and vaccines. The Saint-Amand-Les-Eaux site, from which 130 million doses of vaccine come out each year, is an essential link in the infrastructure built in Europe by the British laboratory GSK, which is one of the 5 world leaders in the industry. biopharmaceutical. Saint-Amand-Les-Eaux, which is responsible for the formulation, filling and packaging of vaccines (secondary production), thus works in close collaboration with the Belgian production sites of GSK Vaccines, which manufacture the antigens (primary production) . In particular the Wavre site, which employs nearly 9,000 people. GSK’s R&D is, for its part, divided between the United Kingdom, Italy and Belgium.
Cutting-edge technologies for the manufacture of essential vaccines
In Saint-Amand-Les-Eaux, GSK Vaccines produces a wide range of vaccines for all ages and for 125 countries. Among them are pediatric vaccines against diphtheria, tetanus and whooping cough, against poliomyelitis, but also vaccines to immunize adults against hepatitis A&B, shingles, or seasonal flu, which still kills too many people. old every winter. The challenge, on the northern site, is to ensure the perfect sterility of the products, from the formulation of the vaccines to the filling of the vials and syringes, including the loading of the freeze-dryers. Processes that require complex and innovative technologies… and technicians trained to master them. As such, the efficiency, commitment and know-how inherited from the region’s industrial past played a major role in the choice of location for this site by GSK, courted by many other European cities.
Mosquirix, the only vaccine in the world against malaria
Also known as Malaria, this disease still affected, according to the WHO, 241 million people worldwide in 2020, causing 627,000 deaths. It is an understatement to say that the teams at Saint-Amand Les Eaux are proud to contribute to the manufacture of Mosquirix, a revolutionary antimalarial which has just been prequalified by the WHO for mass distribution in sub-Saharan African countries. , to protect children there, who are particularly affected by this virus.
At a time when many are wondering about the meaning of their work, GSK employees can be proud to put their energy at the service of a useful cause, within a group that offers everyone the means to train to update their skills to the rhythm of technological innovations and to evolve throughout their career.
Find out more: https://fr.gsk.com/fr-fr/carrieres/